Vigil Neuroscience Q2 2025 Earnings Report

Vigil Neuroscience EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.44
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Vigil Neuroscience Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vigil Neuroscience Announcement Details

• Quarter: Q2 2025
• Date: 8/12/2025
• Time: N/A
• Conference Call Date: Tuesday, August 5, 2025
• Conference Call Time: 12:30PM ET

Vigil Neuroscience (NASDAQ:VIGL) is a clinical-stage biotechnology company dedicated to developing immune-based therapeutics for neurodegenerative disorders. Headquartered in South San Francisco, the company leverages a proprietary platform that integrates immunosequencing and cellular profiling to uncover the immune drivers of diseases affecting the central nervous system. Vigil’s research focuses on translating insights into novel therapeutic candidates designed to modulate pathogenic immune responses in the brain and spinal cord.

At the core of Vigil’s approach is its ImmunoSignature™ discovery platform, which enables high-resolution analysis of cerebrospinal fluid and peripheral blood cells from patients with conditions such as multiple sclerosis, Alzheimer’s disease and other neurodegenerative syndromes. By identifying disease‐associated immune cells and pathways, the company prioritizes targets that are most likely to deliver meaningful clinical benefit with an improved safety profile compared to broadly immunosuppressive treatments.

Vigil’s pipeline features VGL101, an antibody‐drug conjugate currently in early clinical evaluation for progressive multiple sclerosis, as well as preclinical programs aimed at addressing Alzheimer’s disease and amyotrophic lateral sclerosis. The company collaborates with academic institutions and industry partners to advance its candidates through IND-enabling studies and human trials, with a goal of bringing first-in-class therapies to patients in need.

Founded in 2019, Vigil Neuroscience is led by CEO Gustavo Suter de Py and a management team with extensive experience in neurology, immunology and drug development. With operations spanning North America and Europe, Vigil is positioned to expand its global reach through strategic alliances and ongoing clinical research initiatives.